Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | HTR7 | P34969 | 2/20 | 0.32 |
| ▸ | CBX7 | O95931 | 1/20 | 0.32 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.32 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.32 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1152137 | 0.82 | IDO1 (0.36) | CYP46A1IDO1HTR7CBX7CDYL2 | |
| SCHEMBL1153094 | 0.82 | ELOVL6 (0.33) | CYP46A1IDO1AKR1B1 | |
| SCHEMBL1152904 | 0.81 | CYP46A1 (0.41) | CYP46A1IDO1HTR7CBX7CDYL2 | |
| SCHEMBL1152736 | 0.80 | CYP46A1 (0.39) | CYP46A1IDO1HTR7CBX7CDYL2 | |
| SCHEMBL1152520 | 0.79 | HTR7 (0.39) | CYP46A1IDO1HTR7CBX7CDYL2 | |
| SCHEMBL1152471 | 0.78 | CYP46A1 (0.34) | CYP46A1IDO1HTR7CBX7CDYL2 | |
| SCHEMBL6715061 | 0.73 | DRD4 (0.37) | CYP46A1 | |
| SCHEMBL1153810 | 0.71 | CYP46A1 (0.42) | CYP46A1IDO1CBX7CDYL2CDYL | |
| SCHEMBL1153478 | 0.70 | CYP46A1 (0.39) | CYP46A1IDO1CBX7CDYL2CDYL | |
| SCHEMBL1153065 | 0.70 | CYP46A1 (0.39) | CYP46A1IDO1CBX7CDYL2CDYL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023955-A1 | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors | RODGERS JAMES D (US) | 2004-02-05 | — | — | US | claimed |
| US-6596729-B2 | Especially in combination with one or more HIV reverse transcriptase inhibitors, HIV protease inhibitors, fusion inhibitors, and/or CCR-5 | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-22 | — | — | US | claimed |
| US-20020107261-A1 | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors | DUPONT PHARMACEUTICALS COMPANY | 2002-08-08 | — | — | US | claimed |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| US-6969721-B2 | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors | BRISTOL-MYERS SQUIBB PHARMA (US) | 2005-11-29 | — | — | US | disclosed |
| US-20040023955-A1 | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors | RODGERS JAMES D (US) | 2004-02-05 | — | — | US | disclosed |
| US-6596729-B2 | Especially in combination with one or more HIV reverse transcriptase inhibitors, HIV protease inhibitors, fusion inhibitors, and/or CCR-5 | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-22 | — | — | US | disclosed |
| US-20020107261-A1 | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors | DUPONT PHARMACEUTICALS COMPANY | 2002-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | CYP46A1 1649/4885IDO1 4755/4885HTR7 4258/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | CYP46A1 1649/4885IDO1 4755/4885HTR7 4258/4885 |
| US-20040023955-A1 | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors | TYMP, POLRMT, DPYD | CYP46A1 1013/4885IDO1 579/4885HTR7 1449/4885 |
| US-20020107261-A1 | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors | TYMP, POLRMT, DPYD | CYP46A1 1013/4885IDO1 579/4885HTR7 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.